EPLAW PATENT BLOG

UK – Eli Lilly v. Genentech / referral to CJEU

Posted: March 11th, 2019

Eli Lilly And Company & Ors v Genentech, Inc [2019] EWHC 387 and 388 (Pat) (01 March 2019) This was a claim brought by Eli Lilly and Company (“Lilly”) for revocation of Genentech’s patent EP (UK) No. 1,641,822 (the “Patent”) entitled “IL-17A/F heterologous peptides and therapeutic uses thereof”. Genentech does not have a marketed product […]

READ MORE

UK – Supreme Court / Warner-Lambert v. Mylan & Actavis / second medical use / plausibility

Posted: November 14th, 2018

The UKSC has introduced a new test for the infringement of Swiss form second medical use claims and clarified the application of the test for plausibility of purpose-limited claims, by Tim Powell, Bethan Hopewell, Siddharth Kusumakar and Joel Coles, Powell Gilbert LLP  The United Kingdom Supreme Court (UKSC) today handed down its highly-anticipated judgment in the […]

READ MORE

NL – LEO Pharma v. Sandoz

Posted: February 21st, 2018

LEO Pharma A/S v. Sandoz, Court of Appeal of The Hague, the Netherlands, 7 November 2017, published 12 February 2018, Case no. ECLI:NL:GHDHA:2017:4029 LEO Pharma is the holder of the European patent EP 2 455 083 B1 titled “Pharmaceutical composition for dermal use comprising calcipotriol and betamethasone for treating psoriasis”. The patent was granted on […]

READ MORE

NL – LEO Pharma v. Sandoz / Court of Appeal

Posted: December 11th, 2017

LEO Pharma v. Sandoz, Court of Appeal The Hague, 7 November 2017, 200.195.459/01, with thanks to Daan de Lange and Rien Broekstra, Brinkhof, for providing the decision as well as an English translation thereof LEO Pharma A/S (‘LEO Pharma’) is holder of EP 2 455 083 (EP 083), which claims a ‘pharmaceutical composition for dermal use […]

READ MORE

NL – Sandoz v. Astrazeneca / Appeal

Posted: November 2nd, 2017

Sandoz B.V. v. Astrazeneca AB, Court of Appeal The Hague, The Netherlands, 31 October 2017, Case No. 200.200.332/01, with thanks to Willem Hoyng and Theo Blomme, HOYNG ROKH MONEGIER, for submitting the case including an English and German translation thereof Astrazeneca markets FASLODEX which is used for the treatment of oestrogen hormone dependent breast cancers. […]

READ MORE